ADTX — Aditxt, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1726711 ·
Last close
$0.00
Market Cap
$4.09M
52W High
$21845.16
52W Low
$0.00
ADV30
25,510,918
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 12,159 | 2,868 | -4,361,863 | -15,947,725 | 13,906,364 | 268,852 | 49,080,750 |
| Dec 2025 | 425 | -31 | -4,669,584 | -4,701,679 | 16,516,781 | 3,198,599 | 12,563,099 |
| Sep 2025 | 748 | 16 | -3,140,630 | -24,045,405 | 11,799,639 | 163,041 | 20,658,817 |
| Jun 2025 | 1,004 | -1 | -6,152,395 | -7,256,808 | 32,691,232 | 323,679 | 20,696,368 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,553,676
Investing CF
$-2,449,122
Financing CF
$20,795,234
CapEx
$-10,379
Dividends Paid
—
Buybacks
$-2,549,373
EPS Diluted TTM
$-275092.23
As of
2026-09-06
Balance + Analyst (yfinance extras)
Retained Earnings
$-225,756,495
Inventory
$128,366
Receivables
$11,974
ST Investments
—
EBIT TTM
$-50,941,885
Pretax Income TTM
$-53,023,778
Interest Exp TTM
$2,081,893
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$14,336
EBITDA
$-18,075,768
Free Cash Flow
$-12,346,033
Enterprise Value
$2,072,930
Total Cash
$268,852
Total Debt
$4,233,669
Shares Out
997,976,542
Trailing EPS
$-1380.80
Book Value
$-861.43
ROE
—
ROA
-50.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,195 | -19,570,724 | -41,714,201 | 16,516,781 | 12,563,099 | 5,609,704 | -25,688,359 |
| Dec 2024 | 133,985 | -27,863,698 | -34,446,486 | 32,144,390 | 31,052,994 | 1,674,576 | -16,762,121 |
| Dec 2023 | 645,176 | -26,062,425 | -32,380,839 | 44,578,327 | 28,531,558 | 16,056,377 | -19,203,667 |
| Dec 2022 | 933,715 | -24,936,160 | -27,649,876 | 10,735,249 | 5,528,942 | 5,206,307 | -22,392,006 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-11.29
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ERNA | Ernexa Therapeutics Inc. | $4.05M | $3.47 | — |
| CVKD | Cadrenal Therapeutics, Inc. | $4.00M | $1.12 | — |
| ELAB | PMGC Holdings Inc. | $3.87M | $4.78 | — |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | $4.40M | $1.25 | — |
| GRI | GRI Bio, Inc. | $4.59M | $2.10 | — |
News headlines (Yahoo Finance, 1h cache)
ADTX Stock Surges 40% Overnight: New 10% Holder Emerges After Aditxt’s Ignite Proteomics SPAC Deal
2026-06-23 05:29 · Yahoo
ADTX Stock Rockets 90% Premarket: What's Fueling Rebound After A Record 22-Day Selloff?
2026-06-11 08:34 · Yahoo
Aditxt and Ignite announce merger plans with strategic partner
2026-06-10 11:09 · Yahoo
Why Is ADTX Stock In Spotlight Today?
2026-06-09 16:47 · Yahoo
Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million
2026-06-09 11:45 · Yahoo
Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders
2026-06-01 12:15 · Yahoo
ADTX Stock Loses Nasdaq Listing After Seven Reverse Splits Fail To Restore Compliance: Why Is Retail Still Bullish?
2026-06-25 08:06 · Yahoo
Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection
2026-06-08 12:15 · Yahoo
Wall Street Set to Open Higher Wednesday as Investors Dissect Mixed Jobs Report, Look Ahead to Thursday's Inflation Data
2025-12-17 13:53 · Yahoo
Evofem Announces Voting Results from Special Meeting of Stockholders
2025-10-20 20:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.